| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 11.64 | -0.47 (-3.88%) | 3.90 - 13.07 | 60.8 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 12.06 |
|---|---|
| Previous Close | 12.11 |
| Day's Range | 11.58 - 12.06 |
| Market Cap | 333.9M |
| Avg Volume (10 Day) | 70.3K |
| Price/Earnings (Trailing 12 Mo.) | 31.1x |
| Earnings Per Share (Trailing 12 Mo.) | 0.39 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Lannett Names James Maher to Board of Directors
Business Wire - Monday 06/03/2013 7:53 AM ET
| LCI | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 29.93% | |
| Net Income Growth (1yr) | 1,569.83% | |
| Total Debt/Equity | 0.05 | |
| LT Debt/Equity | 0.05 | |
| Earnings Yield | 3.22% | |
| Price/Sales | 2.37 |
| Company | Last | Change |
|---|---|---|
| Depomed Inc | 5.84 | -3.31% |
| Sucampo Pharmaceuticals Inc | 6.87 | -2.83% |
| SciClone Pharmaceuticals Inc | 4.87 | 0.00% |
| Synergy Pharmaceuticals Inc | 4.81 | -3.02% |
| Simcere Pharmaceutical Group | 9.48 | 0.00% |
Data is delayed by at least 15 min.